Ticker

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, March 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that it will release its financial and operational results for the quarter and year ended December 31, 2025, after financial markets close on March 24, 2026. The Company's fourth fiscal quarter and year end 2025 financial and operational results will…

NEW YORK, Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of shareholders of Quantum Biopharma Ltd. ("Quantum" or the "Company") (NASDAQ: QNTM).

New class action for Quantum (QNTM) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 2/23/2026.

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma, Ltd., (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”). Quantum investors have until February 23, 2026 to file a lead plaintiff motion.